Microneedling in Combination with Topical Pimecrolimus 1% versus Topical Pimecrolimus 1% for the Treatment of Refractory Stable Vitiligo: A Randomized Clinical Trial

Table 4

Comparison of numerical indices of patients’ DLQI scores in monotherapy and combination therapy.

Treatment method	Pimecrolimus			Combination of microneedling and pimecrolimus			Kruskalovalis test
DLQI	Mean standard deviation	Median	Interquartile range	Mean standard deviation	Median	Interquartile range
Before treatment	20.50 (1.65)	20.50	(22, 19)	20.73 (1.83)	21	(22, 19)	0.937
After 2 weeks	20.64 (1.59)	21	(22, 19)	20.73 (1.62)	21	(22, 19)	0.953
After 1 month	20.67 (1.23)	21	(22, 20)	20.33 (1.49)	21	(22, 19)	0.812
After 45 days	20.80 (1.32)	21	(21, 20)	20.20 (2.04)	20	(22, 19)	0.699
After 2 months	20.67 (1.49)	21	(22, 19)	20.00 (2.03)	20	(21, 18)	0.492
After 75 days	21.00 (1.51)	21	(22, 20)	19.07 (2.57)	19	(21, 18)	0.091
After 3 months	20.80 (1.47)	20	(22, 20)	18.47 (3.42)	18	(22, 15)	0.132
After 6 months’ follow-up	20.80 (1.74)	21	(22, 19)	18.47 (3.46)	18	(22, 15)	0.149
Friedman test	0.943			0.002